Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03290937 · ClinicalTrials.gov registry record · Phase 1
Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT03290937: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT03290937 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03290937, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This phase I trial studies the best dose and side effects of irinotecan hydrochloride when given with utomilumab and cetuximab in treating patients with colorectal cancer that has spread to other places in the body (metastatic). Monoclonal antibodies, such as utomilumab and cetuximab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving utomilumab, cetuximab, and irinotecan hydrochloride may work better in treating patients with colorectal cancer.
Interventions
- BIOLOGICAL Cetuximab
- DRUG Irinotecan Hydrochloride
- BIOLOGICAL Utomilumab
- OTHER Pharmacodynamic Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2017-12-27 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03290937
The ClinicalTrials.gov registry entry for NCT03290937 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cetuximab is the first listed.
NCT03290937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03290937 about?
NCT03290937 is a clinical study titled "Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer". This phase I trial studies the best dose and side effects of irinotecan hydrochloride when given with utomilumab and cetuximab in treating patients with colorectal cancer that has spread to other places in the body (metastatic). Monoclonal antibodies, such as utomilumab and cetuximab, may interfere ...
What is the current status of trial NCT03290937?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2017-12-27. Estimated completion is 2025-12-30.
What interventions are being tested in trial NCT03290937?
The interventions under investigation include: Cetuximab (BIOLOGICAL), Irinotecan Hydrochloride (DRUG), Utomilumab (BIOLOGICAL), Pharmacodynamic Study (OTHER).
Who is sponsoring clinical trial NCT03290937?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.